- Wave of Debt Payments Facing US Government
- US Job Losses to Bottom out Next Quarter: NABE
- Obama Jobs Forum May Be More Political Than Practical
- Late Payments on Credit Cards Drop in Third Quarter
- Smallest US Businesses Borrowing Again: PayNet
- Little Sign of Inflation on the Horizon: IMF
- Kraft Weighs Higher Cadbury Bid as Rivals Circle
- MBS Program Should be Extended: Fed's Bullard
- Tyson Food Profit Beats Estimates
- Losey: Asset Allocation At Retirement
- Farrell: Obama Hectored, Ignored and Restricted?
- Don't Dwell on Investment Mistakes; Move on, Like Buffett
- CNBC VIDEO: Warren Buffett & Bill Gates 'Walk & Talk' at Columbia University
- U.S. Stocks Slip, Dollar Rises
- How Stock Investors Can Play Holiday Travel
- Time Lapse World Series Is A Great Play
- Hirschhorn: Greed...or Fear
- My Top 10 Tech Toys for the Holidays
- Ohio, other states giving venison donations a lift
- Macquarie sells interest in local power business
- NM wants company to take responsibility for cavern
- Retirement readiness index says if you're on track
- Transocean's Saltiel tapped for COO position
- China tells banks to control lending
- Denied relief, W.Va. schools ready to sue
- New Hampshire considering paid sick leave mandate
- Travelzoo's Loughlin to become CEO in 2010
Text Size 
CAMBRIDGE, Mass. - Alkermes Inc. said a late stage clinical trial shows its drug Vivitrol, which is used to help alcoholics quit drinking, also helped opioid addicts stay off drugs.
Subjects who were injected with Vivitrol once per month were more likely to pass a urine test than patients who received a placebo injection, Alkermes said. The drug also met secondary goals, as subjects reported a lower craving for drugs, and half of the subjects were clean in at least 90 percent of their drug tests.
The subjects were addicted to opioid drugs including heroin. Before participating in the trial, they had to stay off drugs for at least a week.
Vivitrol is an extended-release form of naltrexone. Alkermes said it will ask for approval to market Vivitrol for opioid addiction in the first half of 2010. In morning trading, its shares gained 15 cents to $8.06.
The trial included 250 patients. After the first month of the study, they took one urine test per week, and were also asked about their drug use. The study lasted six months.
The most common side effects were insomnia and inflammation of the nose and throat, Alkermes said.
Print
Email
- Warren Buffett and Bill Gates discuss the economy and other subjects with CNBC's Becky Quick.
- The show attracts a big TV audience every year, but this year it may take on even more importance.
- …you'll want to be prepared. Tips for getting the most out of the post-Thanksgiving shopping frenzy.
- Congressman Ron Paul explains to Squawk Box why he’s pushing legislation to audit the Federal Reserve.
- A Macau casino will open Asia's first Michael Jackson shrine after its owners made a key purchase at a US auction.
- CNBC’s technology reporter Jim Goldman guides you through the best gadgets to buy this holiday season.
Data is a real-time snapshot *Data is delayed at least 15 minutes